Cardiff Oncology, Inc. Earnings Per Share Diluted

• Cardiff Oncology, Inc. showed an increase of +27.4% in Earnings Per Share Diluted from 2024 to 2025.
• This data is from Cardiff Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
• XBRL data for this metric is available from 2012 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 13 years of available data (2012 to 2025), Cardiff Oncology, Inc.'s Earnings Per Share Diluted has grown by 22.5%.
• Historical annual values: Fiscal year 2025: $0.69 (loss) per share | Fiscal year 2024: $0.95 (loss) per share | Fiscal year 2023: $0.93 (loss) per share | Fiscal year 2022: $0.89 (loss) per share | Fiscal year 2021: $0.73 (loss) per share | Fiscal year 2020: $1.08 (loss) per share | Fiscal year 2018: $8.26 (loss) per share | Fiscal year 2017: $51.76 (loss) per share | Fiscal year 2016: $1.37 (loss) per share | Fiscal year 2015: $1.21 (loss) per share | Fiscal year 2014: $0.88 (loss) per share | Fiscal year 2013: $0.70 (loss) per share | Fiscal year 2012: $0.89 (loss) per share.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026